Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs

Core Insights - Defence Therapeutics Inc. has received a 30-day extension approval from the Canadian Securities Exchange for its non-brokered private placement of units priced at $0.50 per unit [3] - The first tranche of the offering closed on October 30, 2024, raising gross proceeds of $775,000 from the sale of 1,550,000 units [3] - The upcoming tranche of financing will support the development of Defence's preclinical radiopharmaceuticals and antibody-drug conjugates (ADCs) programs, utilizing its proprietary Accum® technology platform [4] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing radio-immuno-conjugates and ADC products, along with novel immune-oncology vaccines [5] - The core technology of Defence is the ACCUM® platform, which allows for precision delivery of therapeutic agents to target cells, enhancing efficacy against cancer and infectious diseases [5]